Protein crystallography and drug discovery: recollections of knowledge exchange between academia and industry

Tom L. BlundellIUCrJ 2017 · DOI

TL;DR

This paper chronicles the evolution of structure-guided drug discovery, highlighting how breakthroughs in protein crystallography, driven by a dynamic exchange between academia and industry, have led to life-saving medicines. It argues against a "linear model" of innovation, emphasizing the crucial role of cross-pollination of ideas from diverse research ecosystems.

What Problem Does This Paper Address?

The paper addresses the historical development and ongoing impact of structure-guided drug discovery. It aims to illustrate how understanding the three-dimensional structures of biological molecules, primarily through protein crystallography, has revolutionized the design of new medicines. A key underlying theme is challenging the notion that scientific innovation flows solely from academic institutions to industry, instead showcasing a more complex and collaborative ecosystem where ideas and expertise are shared bidirectionally. This is particularly relevant in the context of developing treatments for diseases ranging from cancer and diabetes to infectious diseases.

Methods

The paper primarily discusses the application of protein crystallography as the foundational technique. This involves determining the atomic and molecular structure of proteins by analyzing the diffraction patterns produced when X-rays are passed through a crystal of the protein.

Beyond basic crystallography, the paper highlights several key methodological advancements and approaches:

  • Isomorphous Replacement: A technique used to solve the "phase problem" in crystallography, crucial for determining the electron density map and thus the protein structure.
  • Comparative Modelling (Homology Modelling): When experimental structures are unavailable, this method uses the known structure of a related protein (a homologue) to build a model of the target protein. Programs like COMPOSER and MODELLER are mentioned.
  • Fragment-Based Drug Discovery (FBDD): This approach screens small, low-molecular-weight molecules (fragments) that bind weakly to specific "hotspots" on a target protein. These fragments are then iteratively grown or linked to create more potent and selective drug candidates. Techniques like X-ray crystallography, NMR, SPR, and thermal shift assays are used for fragment screening and validation.
  • Structure-Guided Design: The overarching principle where knowledge of a protein's 3D structure is used to rationally design molecules that can interact with it, either to inhibit or activate its function. This includes designing transition-state analogues and molecules that exploit specific binding pockets.
  • Automated Crystallography: Advances in robotic sample handling and data collection at synchrotrons have significantly accelerated the structure determination process.

Datasets

Not explicitly discussed in terms of "datasets" in the machine learning sense. However, the paper relies heavily on:

  • Known protein structures: Primarily from X-ray crystallography, which are deposited in databases like the Protein Data Bank (PDB). Examples include insulin, haemoglobin, pepsin, renin, and HIV protease.
  • Chemical libraries: Collections of small molecules used in drug screening, particularly in the context of fragment-based drug discovery.

Key Insights and Ideas

  • The "Linear Model" is a Myth: The paper strongly argues against the idea that innovation flows only from academia to industry. It provides numerous examples where industry contributed crucial insights, materials (like insulin from Boots Pure Drug Company), or optimization techniques that were vital for academic research, and vice-versa.
  • Interdependence of Academia and Industry: The development of structure-guided drug discovery is presented as a testament to successful collaboration. Academic research provides fundamental understanding, while industry offers resources, scale, and a focus on practical application, leading to drug approvals.
  • Evolution of Drug Discovery Paradigms: The paper traces the shift from traditional drug discovery to structure-guided approaches, and then to fragment-based drug discovery, each representing a significant advancement in efficiency and rational design.
  • The Power of "Hotspots": FBDD highlights the importance of identifying specific, high-affinity binding regions ("hotspots") on target proteins, which can be exploited by small molecules.
  • Beyond Active Sites: The paper points to the increasing importance of targeting protein-protein interactions and regulatory systems, moving beyond traditional enzyme active sites, especially for achieving selectivity.
  • Knowledge Exchange as the Engine: The core message is that the continuous exchange of knowledge, techniques, and ideas between academic and industrial researchers is the driving force behind successful drug discovery.

Key Results

  • Numerous Drug Approvals: Structure-guided drug discovery has led to the approval of new drugs for cancer, diabetes, and infectious diseases by the FDA.
  • Development of HIV Antivirals: The understanding of HIV protease structure, informed by academic research and industrial collaboration, was critical for developing effective AIDS antivirals.
  • Successful FBDD Applications: Examples include vemurafenib (BRAF inhibitor for skin cancer), venetoclax (BCL-2 inhibitor for CLL), and ribociclib (CDK4 inhibitor for breast cancer), all developed through fragment-based approaches.
  • Targeting Challenging Interactions: FBDD has shown promise in targeting protein-protein interactions (e.g., BRCA2-RAD51) and infectious diseases (e.g., tuberculosis), areas previously considered difficult for drug development.

Limitations and Future Work

  • Limitations of Comparative Modelling: While useful, comparative modelling relies on the availability of homologous structures and can be less accurate for proteins with low sequence identity to known structures.
  • Challenges in Fragment Elaboration: While fragments bind, growing them into potent and selective drug candidates can be a complex and iterative process.
  • "Druggability" of Protein-Protein Interfaces: Some protein-protein interfaces, particularly those with shallow binding sites, are still considered challenging to target effectively.
  • Future Work: The paper implicitly suggests continued advancements in:
  • High-throughput crystallography and NMR for faster structure determination and fragment screening.
  • Development of more sophisticated computational tools for modelling and design.
  • Exploring new therapeutic areas, such as rare genetic diseases and neglected infectious diseases.
  • Further refining fragment-based approaches for targeting complex biological systems.

Summary updated

Abstract

The development of structure-guided drug discovery is a story of knowledge exchange where new ideas originate from all parts of the research ecosystem. Dorothy Crowfoot Hodgkin obtained insulin from Boots Pure Drug Company in the 1930s and insulin crystallization was optimized in the company Novo in the 1950s, allowing the structure to be determined at Oxford University. The structure of renin was developed in academia, on this occasion in London, in response to a need to develop antihypertensives in pharma. The idea of a dimeric aspartic protease came from an international academic team and was discovered in HIV; it eventually led to new HIV antivirals being developed in industry. Structure-guided fragment-based discovery was developed in large pharma and biotechs, but has been exploited in academia for the development of new inhibitors targeting protein-protein interactions and also antimicrobials to combat mycobacterial infections such as tuberculosis. These observations provide a strong argument against the so-called 'linear model', where ideas flow only in one direction from academic institutions to industry. Structure-guided drug discovery is a story of applications of protein crystallography and knowledge exhange between academia and industry that has led to new drug approvals for cancer and other common medical conditions by the Food and Drug Administration in the USA, as well as hope for the treatment of rare genetic diseases and infectious diseases that are a particular challenge in the developing world.
BibTeX
@inproceedings{blundell2017protein,
  author = {Tom L. Blundell},
  title = {{Protein crystallography and drug discovery: recollections of knowledge exchange between academia and industry}},
  booktitle = {IUCrJ},
  year = {2017},
  doi = {10.1107/s2052252517009241},
}
Figure